Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > NABsys-Affiliated Scientists Receive Two of the Eight ‘Revolutionary Genome Sequencing Technologies – The $1,000 Genome’ Awards from the National Huma

Abstract:
NABsys is Only For-Profit Entity to Receive an Award

NABsys-Affiliated Scientists Receive Two of the Eight ‘Revolutionary Genome Sequencing Technologies – The $1,000 Genome’ Awards from the National Huma

PROVIDENCE, RI | Posted on August 2nd, 2007

NABsys, Inc. announced today that two NABsys-affiliated scientists, Dr. John Oliver, Vice President of Research and Development, and Dr. Xinsheng Sean Ling, NABsys founder and principal academic collaborator and Associate Professor of Physics at Brown University, have received two of the eight "Revolutionary Genome Sequencing Technologies - The $1,000 Genome" awards from the National Human Genome Research Institute (NHGRI), an institute of the National Institutes of Health (NIH). NABsys was the only company, rather than academic lab, to receive an award. The funds will support the development of NABsys' proprietary Hybridization-Assisted Nanopore Sequencing (HANS) platform which the company expects will decrease the cost of whole-genome sequencing to well under $1,000 per person/patient, allowing for the widespread implementation of personalized medicine.

"We are pleased that the NHGRI recognizes the value of the NABsys sequencing platform," said Dr. Barrett Bready, NABsys President and CEO. "The fact that two of the eight scientists to receive ‘$1,000 genome' money were part of the NABsys team is a great validation of our proprietary approach. Additionally, the fact that NABsys is the only company to receive an award this year is further validation of the potential of the platform."

The genetic basis of the most deadly diseases, including heart disease, cancer, and stroke, is not well understood. Understanding the underlying genetics associated with these diseases would lead to a more rational approach to drug design and would allow for personalized, predictive, and preventive medicine. The primary impediment to gaining this understanding and to the implementation of personalized medicine has been the high cost of DNA sequencing.

Dr. Oliver's grant is a two-year $500,000 award made to NABsys. Dr. Ling's grant is a three-year $820,000 award made to Brown University. NABsys has an exclusive licensing agreement with Brown.

"The NABsys sequencing platform, Hybridization-Assisted Nanopore Sequencing combines nanopore sequencing and sequencing by hybridization to create a platform that is much more powerful than either alone," said Dr. John Oliver, Vice President of Research and Development. "These awards will help accelerate the work of our interdisciplinary team as they refine the physics, biochemistry, and computer science associated with HANS."

####

About NABsys, Inc.
NABsys is a nanobiotechnology company developing a next-generation DNA sequencing platform that the company believes will allow an entire human genome to be sequenced for less than $1,000, ultimately enabling personalized medicine. The company’s platform, Hybridization-Assisted Nanopore Sequencing (HANS) uses nanotechnology-based detectors known as nanopores and is being developed in collaboration with researchers at Brown University. The company was founded in 2004 and is located in Providence, RI. To learn more about NABsys, please visit http://www.nabsys.com .

For more information, please click here

Contacts:
Cutler & Company
Andy Cutler
401-743-7842

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Announcements

GTC Shanghai Highlights GF’s Momentum in China: Company shares details of technology roadmap and customer adoption in the world’s fastest-growing market for semiconductors October 23rd, 2017

Nanobiotix completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma October 23rd, 2017

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) October 23rd, 2017

Nanotube fiber antennas as capable as copper: Rice University researchers show their flexible fibers work well but weigh much less October 23rd, 2017

Grants/Sponsored Research/Awards/Scholarships/Gifts/Contests/Honors/Records

Novel 'converter' heralds breakthrough in ultra-fast data processing at nanoscale: Invention bagged four patents and could potentially make microprocessor chips work 1,000 times faster October 20th, 2017

Bringing the atomic world into full color: Researchers turn atomic force microscope measurements into color images October 19th, 2017

Long nanotubes make strong fibers: Rice University researchers advance characterization, purification of nanotube wires and films October 17th, 2017

Rice U. study: Vibrating nanoparticles interact: Placing nanodisks in groups can change their vibrational frequencies October 16th, 2017

Nanobiotechnology

Nanobiotix completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma October 23rd, 2017

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) October 23rd, 2017

Arrowhead Presents Promising Preclinical Data on Development of ARO-AAT for Treatment of Alpha-1 Liver Disease at Liver Meeting(R) 2017 October 23rd, 2017

Spinning strands hint at folding dynamics: Rice University lab uses magnetic beads to model microscopic proteins, polymers October 17th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project